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Background: High rates of anxiety, depression and unmet needs are evident amongst haematological cancer
patients undergoing treatment and their Support Persons. Psychosocial distress may be minimised by ensuring that
patients are sufficiently involved in decision making, provided with tailored information and adequate preparation
for potentially threatening procedures. To date, there are no published studies evaluating interventions designed to
reduce psychosocial distress and unmet needs specifically in patients with haematological cancers and their
Support Persons. This study will examine whether access to a web-based information tool and nurse-delivered
telephone support reduces depression, anxiety and unmet information needs for haematological cancer patients
and their Support Persons.
Methods/Design: A non-blinded, parallel-group, multi-centre randomised controlled trial will be conducted to
compare the effectiveness of a web-based information tool and nurse-delivered telephone support with usual
care. Participants will be recruited from the haematology inpatient wards of five hospitals in New South Wales,
Australia. Patients diagnosed with acute myeloid leukaemia, acute lymphoblastic leukaemia, Burkitt’s lymphoma,
Lymphoblastic lymphoma (B or T cell), or Diffuse Large B-Cell lymphoma and their Support Persons will be eligible to
participate. Patients and their Support Persons will be randomised as dyads. Participants allocated to the intervention
will receive access to a tailored web-based tool that provides accurate, up-to-date and personalised information about:
cancer and its causes; treatment options including treatment procedures information; complementary and alternative
medicine; and available support. Patients and Support Persons will complete self-report measures of anxiety, depression
and unmet needs at 2, 4, 8 and 12 weeks post-recruitment. Patient and Support Person outcomes will be
assessed independently.
Discussion: This study will assess whether providing information and support using web-based and telephone
support address the major psychosocial challenges faced by haematological patients and their Support Persons.
The approach, if found to be effective, has potential to improve psychosocial outcomes for haematological and
other cancer patients, reduce the complexity and burden of meeting patients’ psychosocial needs for health care
providers with high potential for translation into clinical practice.
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Burden of haematological cancers
Haematological malignancies include leukaemias, lymph-
omas and myelomas. Together, haematological malignan-
cies represent 9% of all cancers in the economically
developed regions of the world, and are the fourth most
common type of cancer [1]. Five year relative survival rates
for haematological malignancies vary depending on a
range of factors including the type of cancer and patient
age. In Australia, 5-year relative survival rates range from
24% for acute myeloid leukaemia [2] to 87% for Hodgkin
lymphoma [2].
Psychosocial wellbeing of individuals with haematological
cancers
Treatments for haematological cancers can include inten-
sive chemotherapy, radiotherapy, surgery and haematopoi-
etic stem cell transplantation [3-6]. Treatments are often
urgent and result in debilitating side effects including
nausea, depression, fatigue, vomiting, diarrhoea, oral
mucositis, ovarian failure and infertility [7-9]. Unlike
many other types of cancers, treatment for haematological
malignancies often requires long periods of hospitalisation
and isolation to prevent infections [10,11]. Given the ag-
gressive and complex treatments required, it is not sur-
prising that levels of cancer-related distress are high. Rates
of anxiety amongst haematological cancer patients range
from 22% [12] to 27% [13], and rates of depression be-
tween 17% [12] and 31% [13]. Unmet needs remain high
even after active treatment has ceased, with 27% of haem-
atological cancer survivors reporting unmet needs related
to finances, emotional support, and information [14].
Significant burden placed on support persons
Support Persons are individuals identified by patients as
a main source of support in coping with cancer and its
treatment. They might be the patient’s spouse, child,
other family member, or friend. Support Persons play an
essential role in providing emotional and practical sup-
port to patients [15], however many report that they
have inadequate education and skills to undertake this
role [16]. The significant burden placed on Support Per-
sons often results in psychological morbidity, including
anxiety and depression, as well as adverse effects on
physical health, work and family commitments, and fi-
nances [17-19]. Caregivers of haematological cancer pa-
tients report needing information about managing sideeffects and symptoms, and giving medications [16].
Among the most important factors identified by Support
Persons of haematological cancer patients for improving
their own quality of life are improved communication
with health care providers and receiving education and
support [16].
Evidence-based strategies for reducing psychosocial
distress
A substantial amount of research has examined strategies
to reduce psychosocial distress among individuals with
cancer. Although little work has been done with patients
diagnosed with haematological cancers, the substantial
amount of research with other cancer patient groups sug-
gests psychosocial distress can be minimised by:Ensuring that patients are involved in decision making
Decisional support for treatment has been linked to a
number of positive outcomes including greater knowledge,
more realistic expectations and a better match between
patient values and decisions [20]. There is considerable
variation, however, in patient preferences for the extent of
involvement in decision making regarding their cancer
care [21]. Therefore the ability of clinicians to accurately
identify patient preferences for involvement in treatment
decisions is critical. Research has shown that in 58% of
cases clinicians do not accurately assess patient prefer-
ences [21,22]. Effective forms of communication that ac-
count for individual factors, such as health literacy and
patient preference, are essential to provide patients with
an opportunity to take an active role in decision making
about their health care.
Providing tailored information
The principle of patient-centeredness endorsed by the
Institute of Medicine promotes health care that is tai-
lored and responsive to patient needs [23]. Providing
patients with information about treatment, including
both procedural and sensory information, can reduce
patient distress and improve recovery [24-26]. Despite
these potential benefits, many cancer patients report
high levels of unmet information needs [27]. Guidelines
for the psychosocial care of cancer patients recommend
that information is tailored to individual circumstances
and preferences for amount and type of information
[28]. Tailoring is likely to be particularly important for
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sons given that haematological cancers are a very diverse
group of diseases that often require a range of complex
and rapidly changing treatment regimes. Customising diag-
nosis and treatment information to ensure concordance
with the medical circumstances of the individual may help
to prevent unnecessary anxiety as a result of viewing infor-
mation that is not relevant [28]. Providing an opportunity
for patients and their families to talk to an experienced
cancer nurse can improve understanding and reduce psy-
chosocial morbidity [28]. Patients vary in their preferences
for the amount of information they wish to receive, the
way the information should be presented and the level of
detail they would like to know [29]. Tailoring information
to match individual preferences and health literacy can
improve psychosocial outcomes and recall of informa-
tion [23,28,30].Preparing patients for potentially threatening procedures
High levels of anxiety can result in poor recall of infor-
mation, which has implications for patient adherence
to recommendations for care [31]. The prevalence of
pre-treatment anxiety is very high among patients
undergoing cancer treatment [32]. While there is evi-
dence that preparing patients for potentially threaten-
ing medical procedures can reduce anxiety and pain,
and improve recovery, information provision prior to
treatment is often inadequate [28]. Therefore, there is
potential to improve psychosocial outcomes for cancer
patients via integration of preparatory information into
routine care.
Providing psychological therapies
There is substantial evidence for the effectiveness of psy-
chological therapies, including supportive and cognitive-
behavioural therapies, for reducing treatment-related
distress in cancer patients [28]. Meta-analyses have
demonstrated the effectiveness of psychological therapies,
finding significant improvements across a range of out-
comes for cancer patients including: emotional adjustment,
social functioning, quality of life, anxiety, depression, and
physical symptoms. [33,34] While there is demonstrated
success in improving outcomes for patients who access
psychological therapies, the high prevalence of anxiety12 13,
depression12 13 and unmet needs [14] among individuals
with cancer suggest there may be barriers to accessing such
treatments. Barriers to the use of psychological support
services reported by patients include a lack of patient
awareness of services, lack of provider referral/endorse-
ment, inconvenient location of services, lack of willingness
to talk to a stranger or therapist about personal issues, and
difficulty scheduling appointments around treatment and
other commitments [35,36].The Internet is an ideal platform to provide support
which aligns with the evidence base
Most Australians have access to the Internet (83%) [37],
and it is frequently reported as an important source for
obtaining medical information [38]. There are a number of
advantages in using web-based interventions for informa-
tion provision and psychosocial support: information can
be tailored based on user circumstances (e.g. diagnosis),
needs and preferences using algorithms; users can exercise
control over the type and level of information they receive
and the frequency with which they access the information;
it allows for real-time customisation based on user needs
and preferences (e.g. text size); information can be pre-
sented in a range of formats including text, graphics
and videos to suit the literacy levels of users, thereby
improving understanding and recall; and web-based
interventions can incorporate interactive features to
facilitate communication and information sharing, such
as email and discussion forums. From a service pro-
vider perspective, a major advantage of web-delivered
interventions is that it enables central delivery of stan-
dardised evidence-based information independent of
resource constraints of individual health care settings
[39]. A web-based approach can also be used to facili-
tate access to information and support for Support
Persons.
Web-based interventions to improve psychosocial
outcomes for patients and their Support Persons
Several reviews have investigated the effectiveness of web-
based approaches for patient education and psychosocial
support. [40-43] These reviews have demonstrated some
evidence in favour of web-based interventions for improv-
ing patient outcomes, including knowledge, healthy behav-
iours, social support and psychosocial wellbeing. However,
the conclusions drawn from the literature are limited by
mixed findings and methodological weaknesses of the
available studies. Furthermore, given that there are no
published studies evaluating web-based interventions de-
signed to improve psychosocial outcomes specifically for
patients with haematological cancers and their Support
Persons, there is a need to further develop this evidence
base. The potential for web-based interventions to im-
prove psychosocial outcomes for haematological cancer
patients is likely to be enhanced by ensuring that interven-
tions are integrated, tailored to the needs and preferences
of the patient, involve Support Persons, provide support
for treatment decision making and preparation for
treatment, and provide support across the pre-treatment,
treatment and post-treatment phases of illness.
Aims
This study will examine, using a randomised controlled
trial, whether an integrated approach that includes access
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telephone support reduces for both haematological
cancer patients and their Support Persons (i) unmet in-
formation needs (primary outcome); and (ii) depres-
sion; and (iii) anxiety (secondary outcomes); at 2, 4, 8
and 12 weeks follow up.
Hypotheses
It is hypothesised that:
(i) Patients who are allocated to the intervention group
will have a 0.45 standard deviation lower mean total
score on the Health System and Information Needs
Domain of the Supportive Care Needs Survey Short
Form (SCNS-SF34) (primary outcome), and 0.45
standard deviation lower anxiety and depression
scores as measured by the Hospital Anxiety and
Depression Scale (HADS) (secondary outcomes),
compared to patients who are allocated to the
control condition;
(ii)Support Persons who are allocated to the
intervention group will have a 0.45 standard
deviation lower unmet information needs score as
measured by the Support Persons Unmet Needs
Survey (SPUNS) (primary outcome), and a 0.45
standard deviation lower depression and anxiety
score as measured by the Depression and Stress
Scale-21 (DASS) (secondary outcomes), compared to
Support Persons who are allocated to the control
condition.
Method
Study design
This study is a non-blinded, parallel-group, multi-centre
randomised controlled trial comparing the effectiveness of
a web-based information tool and nurse-delivered tele-
phone support with usual care. The primary outcomes
for both patients and Support Persons are unmet infor-
mation needs and the secondary outcomes are anxiety
and depression. All outcomes are assessed a 2, 4, 8 and
12 weeks post-recruitment. This study is funded by a
Cancer Institute New South Wales Translation Program
Grant (10/THS/2-14).
Hospital eligibility
Participants will be recruited from the haematology in-
patient wards of five Australian hospitals located in New
South Wales. These hospitals were selected because they
treated at least 15 eligible participants each year.
Patient and support person eligibility
Patients will be eligible to participate if they are: aged
18 years or older; English speaking; newly diagnosed
with acute myeloid leukaemia, acute lymphoblasticleukaemia, Burkitt’s lymphoma, Lymphoblastic lymph-
oma (B or T cell), or Diffuse Large B-Cell lymphoma;
are potentially making a decision regarding treatment;
have a life expectancy of 2 months or more as judged by
their clinician; and are able to provide informed consent.
Those who have commenced cytotoxic chemotherapy
will be excluded. The included haematological malignan-
cies were chosen to represent aggressive malignancies
that frequently require urgent inpatient treatment. Sup-
port Persons of patients are eligible to participate if they
are: aged 18 years or older; able to provide informed
consent; and are nominated by the patient participant to
be an important source of support in relation to the de-
mands of their cancer diagnosis and treatment. Patients
and Support Persons are not required to have access to
the internet as the intervention will be available to ac-
cess using iPads provided in hospital.
Recruitment and consent procedure
A consecutive sample of haematological cancer patients
and their Support Persons will be recruited. Recruitment
will take place as soon after the time of diagnosis as pos-
sible. Patients will be informed about the research by
their treating doctor and provided with a study informa-
tion statement. Participants who are willing to take part
will complete a consent form which will be co-signed by
their doctor. Consenting patients will be provided with
an information package to pass on to their Support
Person if they wish to do so. The information package
contains a study information statement for the Support
Person detailing the research and what participation
would involve. Support Persons who are willing to take
part in the study will be instructed to complete an
enclosed consent form and return it to the research
team using the reply paid envelope provided. Patients
are eligible regardless of whether they have a participating
Support Person. Support Persons are only eligible to
participate if they are supporting a cancer patient who
has also consented to participate. In the event of the
death or withdrawal of a patient participant, the con-
senting Support Person, if any, will be asked whether
they would like to continue participation.
Randomisation and blinding
Patients will be allocated to either the intervention or con-
trol group depending on the week they are recruited, with
weeks randomly allocated to intervention or control group
across all hospitals throughout the recruitment period.
Support Persons will be allocated to the same group as the
patient. The random allocation sequence will be generated
using an online random number generator distributed by
a research team member not involved in participant re-
cruitment. Participants and health care providers will be
blind to the allocation sequence. Clinical trials nurses
Table 1 Web-based information tool content headings
Domain Content
1. Introduction 1.1 Introduction
2. My cancer and its causes 2.1a Acute myeloid leukaemia
2.1b Acute lymphoblastic leukaemia
2.1c Burkitt’s lymphoma
2.1d Lymphoblastic lymphoma
(B or T cell)
3. What are my treatment
options?
3.1 Chemotherapy
3.1.1 What does chemotherapy involve?
3.1.1.1 What tests will I require before
and during treatment?
3.1.1.2 How is chemotherapy given?
3.1.1.2.1 Cannula
3.1.1.2.2 Central lines
3.1.1.2.3 PICC lines
3.1.1.2.4 Lumbar puncture
3.1.1.3 How long does chemotherapy
take?
3.1.1.4 Where will I have chemotherapy?
3.1.1.5 Who will be involved in my care?
3.1.1.6 What are the safety precautions?
3.1.1.7 How and when will I know if the
chemotherapy has worked?
3.1.2 What are possible side effects?
3.1.2.1 Effects on the blood and
immune system
3.1.2.1.1 Avoiding infection
3.1.2.2 Hair loss or scalp problems
3.1.2.3 Loss of appetite, nausea or
vomiting
3.1.2.4 Constipation or diarrhoea
3.1.2.5 Fatigue
3.1.2.6 Itchy skin and other skin
problems
3.1.2.7 Mouth sores
3.1.2.8 Infertility
3.1.2.9 When to contact your doctor
3.1.3 What happens after
chemotherapy?
3.1.3.1 What happens when I go home?
3.1.3.2 What are the chances of the
cancer coming back?
3.1.3.3 When should I seek medical
assistance?
3.2 Bone marrow transplant
3.2.1 What is bone marrow?
3.2.2 What is a bone marrow transplant?
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the researchers at the start of each week whether partici-
pants recruited over the next week are to be assigned to
the intervention or control conditions. Due to the nature
of the intervention, it is not possible to blind participants
or health care providers to condition allocation. Those
responsible for conducting analysis of outcomes and in-
terpretation of data will be blind to group allocation.
Intervention
Participants randomised to the intervention group will
receive access to a web-based information tool and
nurse-delivered telephone support for the duration of the
study.
Development of web-based information tool
Development of content
The web-based information tool was developed by the
Health Behaviour Research Group, University of New-
castle, Australia, in collaboration with the Department
of Haematology, Royal North Shore Hospital, Australia,
and a multi-disciplinary expert advisory group. The con-
tent of the intervention web program was developed
using patient information resources from the Leukaemia
Foundation Australia, the Cancer Council New South
Wales and Macmillan Cancer Support (UK). Permission
from these organisations was obtained prior to adapta-
tion of materials. All information sources are clearly ac-
knowledged in the web-based information tool. Two
expert advisory groups were convened to review and up-
date content and ensure acceptability and consensus
among clinical haematological cancer professionals. Ex-
pert advisory groups comprised multidisciplinary health
care providers, including haematologists, nurses, clinical
psychologists, dietitians, infectious disease experts and
palliative care coordinators, as well as members of key
patient support organizations. The advisory groups were
responsible for reviewing all intervention materials for
accuracy, completeness, level of detail, and communica-
tion style. Feedback was then collated and discussed at
the advisory group meetings until consensus was
reached regarding the content. Revised versions of the
content were then circulated to members for final review
and feedback. The final version of the web-based tool
includes information on a range of topics, including in-
formation about diagnosis, treatment options, what is in-
volved in each treatment, side effects, self-management
strategies, impact of cancer on day to day life, available
support, complementary and alternative therapies (see
Table 1).
Development of software
Development of the technical aspects of the web-based
tool was undertaken by the Distributed Computing
Table 1 Web-based information tool content headings
(Continued)
3.2.3 Is a bone marrow transplant right
for me?
3.2.4 Types of bone marrow transplants
3.3 Palliative care
3.3.1 What does palliative care involve?
3.3.1.1 How long does palliative care
take?
3.3.1.2 Where would I have palliative
care?
3.3.1.3 Who will be involved in my care?
3.3.1.4 Can my carer access respite care?
3.3.2 Symptom management
3.4 No treatment
3.5 Clinical trials
3.5.1 What is a clinical trial?
3.6 Getting a second opinion
4. Complementary and
alternative medicine (CAM)
4.1 What is CAM?
4.1.1 What is scientific evidence?
4.1.2 Complementary therapies
4.1.3 Alternative therapies
4.2 Why do some people with cancer
choose CAM?
4.3 What types of CAM are there?
4.4 Important safety information
4.5 What should I ask my doctor about
CAM?
4.6 How do I decide?
4.7 Costs
4.8 Finding a complementary therapist
4.8.1 Professional associations
4.9 Talking to complementary therapists
5. Impact of cancer and
treatment on my life
5.1 Family
5.2 Work
5.2.1 Taking time off work
5.2.2 Financial issues
5.3 Education/Studies
5.4 Partner relationships
5.5 Social life
5.6 Body image and sexuality
5.7 Diet
5.7.1 Coping with eating problems and
side effects
5.7.2 How to gain weight
5.7.3 Access to a dietitian
5.7.4 Recipes and snacks
Table 1 Web-based information tool content headings
(Continued)
5.8 Exercise
6. What support is available? 6.1 Emotional support
6.2 Accommodation
6.3 Practical support
6.4 Transport/parking
6.5 Financial assistance
6.6 Support for the family
6.7 Access to wigs
7. Where can I get further
information?
7.1 Websites
7.2 Telephone helplines
7.3 Clinical cancer nurse
8. Discussion Forum 8. Discussion Forum
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Established web design principles [44,45] were employed
to ensure that the tool allows the user to extract the de-
sired information as easily as possible. The site is hosted
on a secure Apache Tomcat server at the University of
Newcastle. A security certificate protects the site and ac-
cess to the site is via secure HTTP (HTTPS). The site
has been written using HTML5, facilitating the provision
of multimedia content and reducing the need for special
software on participant computers. Some server behav-
iour was achieved using code written in Java or PHP.
Modules adapted from public domain content manage-
ment (CMS) software have been used to facilitate gener-
ation and modification of textual content. Video content
uses the capabilities of HTML5. A mySQL database in-
stalled on the web server securely stores user-identified
audit information that can be later collated.Functionality
The information presented in the web-based intervention
tool will be tailored to the circumstances of the individual.
Participants will only be able to view information that is
relevant to their own specific diagnosis and the treatment
options that their treating doctor has nominated as suit-
able for them. Some therapeutic options may be medically
contraindicated due to the patient’s health or age at diag-
nosis. Tailoring to the needs of individuals is further exem-
plified with information presented in multiple formats,
including short videos, text and images to suit different
learning styles and literacy levels of participants. Expand-
able text is provided for sections of information which
may be of a sensitive or potentially distressing nature to
enable participants to exercise more control over the type
of information they wish to view (refer to Figure 1). In
addition, explicit categorisation strategies are used to
Figure 1 Screenshot of Expandable Text Section.
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information summarised into key points.
Participants will be able to search for desired informa-
tion using the topic tabs, expandable side menus and
search function. If participants have additional questions
or concerns about any information contained within the
web-based intervention, an icon is available at the bot-
tom of every page, which allows the participants to send
their questions to the study nurse via automated email
(refer to Figure 2). Participants are also able to ask ques-
tions and connect with other participants in the inter-
vention group via a discussion forum. Participants are
able to create threads on the discussion forum and com-
ment on other users’ threads. The discussion forum is
monitored by the lead clinical researcher.
In order to ensure the acceptability and usefulness of
the information intervention, a feedback mechanism has
been integrated into the web software. Participants in
the intervention group will be asked to indicate whether
they found the information on the web page they are
viewing useful. This data will be collected via a pop-up
window and will occur randomly, up to a maximum of 4
times per user. The custom built software will collate
data on each user’s access behaviour and feedback.Pilot testing
The penultimate version of the web-based information
intervention was pilot tested with a sample of haemato-
logical cancer patients (n = 33). Pilot participants wereasked to rate sections of information and complete a
brief survey about the acceptability of the intervention.
Feedback obtained from consumers was evaluated and
incorporated if recommended changes reflected the
views of the majority. Members of the expert advisory
groups were consulted during this revision process to
ensure the accuracy of amended information.Intervention delivery
Web-based information tool
Participants in the intervention group will gain access to
the web-based information intervention at the time of re-
cruitment. For consenting patients, the treating doctor will
log in to the administrative interface of the intervention
website and complete a brief online form indicating the
patient’s name, date of birth, gender, diagnosis, and the
treatment options that are relevant to the patients’ circum-
stances (see Figure 3). Using this information the web-
based intervention will automatically generate a user ID
for the patient. This user ID will be provided to both the
patient and their Support Person along with detailed in-
structions on how to access the web-based information
tool both in hospital and at home. The information en-
tered into the online form by the clinician will also be used
to tailor the content of the web program.
At least two study iPads (touch screen tablet devices)
will be provided to each hospital for use by inpatients who
have been assigned to the intervention group to access the
web-based information intervention. Outpatients without
Figure 2 Screenshot of Information Icon.
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the intervention while visiting the hospital for outpatient
appointments. Support Persons will be able to use the
iPads when at hospital, and access the web-based tool
using their home internet access. Use of the web-based
information intervention will be self-guided, with no
restriction placed on how and to what extent it is used.
At the time of recruitment, intervention patients will be
provided with a demonstration, to supplement the writtenFigure 3 Screenshot of Administrative Interface.instructions, on how to use the iPad and access the web-
based intervention by a research nurse or study volunteer.
Nurse-delivered telephone support
Intervention patients and Support Persons will also have
access to an experienced haematological cancer nurse.
Participants can contact the cancer nurse via a toll free
telephone number to seek information or ask questions.
Participants will also have the option of contacting the
Bryant et al. BMC Cancer  (2015) 15:295 Page 9 of 13nurse via the information icon in the web-based infor-
mation tool, as described above. An automated email
will be sent to the nurse providing the patient’s first
name, the user’s relationship to the patient, the topic of
the page where the icon was clicked, the question/query
indicated by the user, the contact telephone number in-
dicated by the user, and details of the treating doctor.
The cancer nurse will have experience with addressing
information needs and adjustment issues and will be su-
pervised by the lead clinical researcher (WS).
Usual care
Patients and Support Persons randomised to the con-
trol group will receive usual care. The control condi-
tion reflects the usual process of psychosocial support
and information provision for newly diagnosed haem-
atological cancer patients and their Support Persons.
While usual care may vary slightly between participat-
ing hospitals and clinicians, psychosocial care and
information provision in this early phase of cancer sur-
vivorship usually involves the provision of generic written
material provided by healthcare providers and non-
government patient support organisations such as Cancer
Council and/or Leukaemia Foundation. Participants in theFigure 4 Flowchart of study design.control group may seek and obtain information or support
that is available on the Internet or from other sources, but
will not have access to the web-based intervention or
nurse-delivered telephone support specifically developed
for this trial.
Data collection
Outcome data will be collected from patients and Sup-
port Persons via paper-and-pen surveys at 2, 4, 8 and
12 weeks post-recruitment (refer to Figure 4). These
time points were chosen given the intervention primarily
targets the provision of care at diagnosis and during
treatment, and it is during this time period when pa-
tients are making decisions about and receiving intensive
treatment. Data collection for participants who are in
hospital will be conducted by research nurses or study
volunteers, depending on the preference and policy of
the individual hospital. All research nurses and study
volunteers will receive comprehensive training. The re-
search nurse or study volunteer will visit the participant in
hospital to provide them with the survey package appro-
priate to the time point and answer any questions about
survey completion. Survey packages will be provided to
the participant in an unsealed envelope, allowing them to
Bryant et al. BMC Cancer  (2015) 15:295 Page 10 of 13seal their responses prior to returning the survey to the re-
search nurse or volunteer. Participants who do not wish
to complete the survey are able to seal the envelope and
return it uncompleted. For participants who are not in
hospital, including all Support Persons, surveys will be
sent via mail with a reply paid envelope to allow return of
the completed survey. The study co-ordinator at each par-
ticipating hospital will be requested to keep an up-to-date
record of participants who are discharged or deceased in
order to arrange the appropriate method of data collection
or remove them from the contact list respectively.
A reminder phone call will be made to non-responders
approximately two weeks after the time of the initial
delivery of each survey. Reminder phone calls will only
occur for participants who are not in hospital. For non-
responders who are in hospital, the research nurse or study
volunteer will prompt the participant to either complete
the survey if they wish to do so or return it uncompleted.
Outcome measures
Patients and Support Persons in both the intervention and
control groups will complete self-report measures of un-
met needs, anxiety and depression at 2, 4, 8 and 12 weeks
post-recruitment.
Patient outcomes
Unmet needs will be assessed using the health systems
and information domain of the Supportive Care Needs
Survey - Short Form (SCNS-SF34) [46]. The SCNS-SF34
assesses unmet needs across five domains: (i) psycho-
logical; (ii) health systems and information; (iii) patient
care and support; (iv) physical and daily living; and (v)
sexuality. Participants indicate their level of need for
each item using a five point scale: ‘no need, not applicable;
‘no need, satisfied’; ‘low need’; ‘moderate need’; and ‘high
need’. Domain scores are calculated by summing item re-
sponses within the domain. The SCNS-SF34 has high in-
ternal consistency for each of the five factors (Cronbach
alpha’s 0.86 to 0.96) and good convergent validity [46].
Anxiety and depression will be assessed using the Hos-
pital Anxiety and Depression Scale (HADS) [47]. The
HADS is a 14-item self-report instrument which measures
anxiety (7 items) and depression (7 items) within the last
seven days. Participants respond to each item on a four
point scale with 3 indicating that the symptom is severe or
frequent, and 0 indicating the symptom is absent or al-
most absent. Scores from items are summed to provide an
overall score out of 21 for the anxiety and depression sub-
scales. The HADS has acceptable internal consistency,
construct validity, and discriminant validity [48].
Support person outcomes
Unmet needs for Support Persons will be assessed using
the information and relationships domain of the SupportPersons Unmet Needs Survey (SPUNS) [49], which is a
78-item measure of unmet needs across 6 domains: (i)
Information and relationships; (ii) Emotional needs; (iii)
Personal needs; (iv) Work and finance; (v) Healthcare
access and continuity; and (vi) Worries about the future.
Participants provide responses for each item on a five
point likert scale from ‘no unmet need’ to 4 ‘very high
unmet need’. Domain scores are calculated by summing
item responses and dividing by the number of non-
missing responses within the domain. The SPUNS has
high acceptability, item test-retest reliability, internal
consistency (Cronbach alpha = 0.99), and face, content,
and construct validity [49].
Anxiety and depression will be measured using the
Depression and Stress Scale-21 (DASS-21) [50], a 21-
item self-report instrument which measures depression
(7 items), anxiety (7 items) and stress (7 items). Partici-
pants respond to each item using a four point scale from
‘Did not apply to me at all’ to ‘Applied to me very much
or most of the time’. Scores on each scale (Depression,
Anxiety, and Stress) are calculated by summing item re-
sponses within the scale and multiplying totals by two.
Reliability, convergent validity and discriminant validity
of the total score and three sub-scales of the DASS-21 is
adequate [51,52].
Demographic characteristics
Demographic characteristics including date of birth,
gender, postcode, marital status, education, time since
diagnosis, distance to the cancer centre (for patients
only) and relationship to the patient (for Support Persons
only) will be collected via participant self-report two
weeks post-recruitment.
Process measures
Psychological support service utilisation will be exam-
ined at 12 weeks post-recruitment for patients and Sup-
port Persons in both the intervention and control group.
Participants will be asked whether and how many times
they have accessed psychological support from a range
of services in the past 12 weeks.
Process and acceptability measures (intervention group
only): For intervention patients and Support Persons use
of the program will be monitored via embedded web mon-
itoring tools. Data collected will include the number of
times a participant accesses the web-based intervention,
and the type of information accessed will be recorded by
the website. Use of the 1800 number will also be moni-
tored via a call log. Acceptability and usefulness of the
web-based intervention will be examined via a series of
questions in the Week 4 survey for intervention group
participants. Clinicians will complete a brief assessment of
the perceived acceptability of the intervention at the end
of the recruitment period.
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Patient sample: Assuming a 75% consent rate, 450 patients
will be approached to give a sample of 340 at baseline.
Allowing for 15% attrition, at each follow up, a sample of
145 per group will be available at 4 weeks, 123 per group
at 8 weeks and 105 per group at 12 weeks. Assuming 90%
power and 5% significance level this will enable detection
of differences between groups of, 0.38 standard deviations
(SD) at 4 weeks, 0.41 SD at 8 weeks and 0.45 SD at
12 weeks follow up. There are over 400 patients diagnosed
each year in NSW with the cancers specified in our eligi-
bility criteria. High volume centres will be targeted for re-
cruitment. Current studies being conducted by the group
involving clinic-based recruitment are achieving an 85%
consent rate. These effect sizes are clinically relevant.
Support person sample: For each of the 340 patient par-
ticipants, one Support Person will be recruited. It is antici-
pated that 80% of patients will have a Support Person who
provides data at 4 weeks. Allowing for 15% attrition at
each follow up, a sample of 115 per group will be available
for comparison at 4 weeks, 100 per group at 8 weeks and
85 per group at 12 weeks. Assuming 90% power and 5%
significance level this will enable detection of differences
between groups of 0.4 SD at 4 week follow up and 0.45 SD
at 8 weeks and 0.5 SD follow up. These effect sizes are
clinically relevant.
Statistical analysis
The primary outcome of interest will be scores on the
Health Systems and Information Needs Domain of the
SCNS-34 (patients), and the information and relationships
domain of the SPUNS (Support Persons). Secondary out-
comes will be scores on the anxiety and depression sub-
scales of the HADS (patients) and DASS (Support
Persons). Outcomes will be compared between groups at
each time point using a mixed effects linear regression
that includes data from all time points (including base-
line), with fixed effects for group, time, the interaction be-
tween time and group, and clinic. The model will be
adjusted for age and gender (of participant or Support
Person as appropriate) and robust variance estimates will
be obtained. Treatment group comparisons at each visit
will be estimated by differences in least-square means
from the group by visit interaction and will be presented
as differences in means with 95% Confidence Intervals
and accompanying p values. Primary analysis will involve
complete case analysis, and sensitivity analysis will be per-
formed using multiple imputation to account for missing
data. If the distribution is problematic, we will consider
alternative strategies such as a transformation.
Ethics approval and registration
This study has been approved by the Cancer Institute
NSW Clinical Research Ethics Committee in Australia(NHMRC Committee Code: EC00414) (AU RED Refer-
ence: HREC/11/CIC/24), the Hunter New England Hu-
man Research Ethics Committee (NHMRC Committee
Code: EC00403) (AU RED Reference: HREC/13/HNE/
338) and The University of Newcastle Human Research
Ethics Committee (NHMRC Committee Code: EC00144)
(Reference No: H-2012-0011). The study has also been
approved by the local research governance committees
of each participating hospital. Registration number of
the Australian New Zealand Clinical Trials Registry is
ACTRN12612000720819, registered on 5/7/2012.Discussion
Despite the challenges faced by patients with haemato-
logical malignancies and their Support Persons, few in-
terventions have addressed the psychosocial needs of
this group. Currently, there is a lack of up to date, com-
prehensive sources of information for individuals with
blood cancer and their Support Persons that covers the
entire journey from diagnosis into survivorship. This
study will assess whether a web and telephone based ap-
proach to providing information and support addresses
psychosocial challenges faced by haematological patients
and Support Persons. The intervention includes Support
Persons, uses technology to support tailoring, is designed
with integration into routine clinical practice in mind, and
draws on best practice recommendations for the provision
of information. The approach, if found to be effective, has
potential to improve psychosocial outcomes for haematol-
ogy patients and other cancer patients, reduce the com-
plexity and burden of meeting patients’ psychosocial needs
for health care providers and has high potential for transla-
tion into clinical practice.
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